CPHD Insider Trading
CPHD | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at CPHD provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2014-12-03 03:13 | 2014-11-28 | Miller Andrew | Officer - EVP, CFO | OPT+S | $55.75 | 11,250 | $627,188 | 298 | 0.0% |
| 2014-12-03 03:12 | 2014-11-28 | PERSING DAVID H | Director, Officer - EVP, Chief Med/Tech Officer | OPT+S | $55.78 | 15,000 | $836,750 | 4,062 | 0.0% |
| 2014-12-02 00:36 | 2014-11-26 | PERSING DAVID H | Director, Officer - EVP, Chief Med/Tech Officer | OPT+S | $54.62 | 75,000 | $4,096,223 | 4,062 | 0.0% |
| 2014-11-26 00:35 | 2014-11-21 | MORTON DEAN O | Director | OPT+S | $53.04 | 651 | $34,532 | 16,334 | 0.0% |
| 2014-11-21 01:54 | 2014-11-18 | MORTON DEAN O | Director | OPT+S | $52.96 | 11,849 | $627,557 | 16,334 | 0.0% |
| 2014-11-18 00:13 | 2014-11-13 | Miller Andrew | Officer - EVP, CFO | OPT+S | $54.75 | 5,625 | $307,969 | 298 | 0.0% |
| 2014-11-18 00:13 | 2014-11-13 | PERSING DAVID H | Director, Officer - EVP, Chief Med/Tech Officer | OPT+S | $54.68 | 5,000 | $273,400 | 4,062 | 0.0% |
| 2014-11-18 00:12 | 2014-11-13 | KOCMOND WARREN C JR | Officer - EVP, Global Operations | OPT+S | $55.00 | 216 | $11,880 | 10,000 | 0.0% |
| 2014-11-11 02:26 | 2014-11-07 | KOCMOND WARREN C JR | Officer - EVP, Global Operations | OPT+S | $51.37 | 325 | $16,695 | 10,000 | 0.0% |
| 2014-11-11 02:25 | 2014-11-07 | RENTON HOLLINGS | Director | OPT+S | $51.07 | 9,375 | $478,781 | 9,517 | 0.0% |
| 2014-11-01 01:26 | 2014-10-31 | MORTON DEAN O | Director | OPT+S | $52.64 | 7,500 | $394,797 | 16,334 | 0.0% |
| 2014-11-01 01:26 | 2014-10-29 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $51.36 | 7,077 | $363,468 | 1,376 | 0.0% |
| 2014-11-01 01:25 | 2014-10-31 | Miller Andrew | Officer - EVP, CFO | OPT+S | $53.84 | 12,167 | $655,108 | 298 | 0.0% |
| 2014-11-01 01:25 | 2014-10-30 | PERSING DAVID H | Director, Officer - EVP, Chief Med/Tech Officer | OPT+S | $53.34 | 20,000 | $1,066,800 | 4,062 | 0.0% |
| 2014-11-01 01:21 | 2014-10-29 | GUTSHALL THOMAS L | Director | SELL | $51.63 | 12,500 | $645,434 | 90,859 | -12.1% |
| 2014-10-29 00:33 | 2014-10-27 | PERSING DAVID H | Director, Officer - EVP, Chief Med/Tech Officer | OPT+S | $51.51 | 15,000 | $772,700 | 3,834 | 0.0% |
| 2014-10-29 00:30 | 2014-10-27 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $50.89 | 207 | $10,534 | 1,182 | 0.0% |
| 2014-10-22 23:15 | 2014-10-20 | RENTON HOLLINGS | Director | OPT+S | $45.85 | 12,500 | $573,168 | 9,517 | 0.0% |
| 2014-10-06 23:21 | 2014-10-03 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $44.52 | 1,271 | $56,591 | 1,182 | 0.0% |
| 2014-08-08 23:34 | 2014-08-07 | KOCMOND WARREN C JR | Officer - EVP, Global Operations | OPT+S | $38.69 | 324 | $12,535 | 0 | 0.0% |
| 2014-07-29 00:28 | 2014-07-25 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $39.79 | 207 | $8,236 | 989 | 0.0% |
| 2014-07-16 02:04 | 2014-07-14 | KOCMOND WARREN C JR | Officer - EVP, Global Operations | OPT+S | $50.00 | 9,375 | $468,750 | 0 | 0.0% |
| 2014-07-16 02:03 | 2014-07-14 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $49.72 | 2,812 | $139,813 | 989 | 0.0% |
| 2014-07-07 23:28 | 2014-07-03 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $48.97 | 1,282 | $62,779 | 989 | 0.0% |
| 2014-03-17 23:08 | 2014-03-13 | Miller Andrew | Officer - EVP, CFO | OPT+S | $55.55 | 17,265 | $959,071 | 4,584 | 0.0% |
| 2014-02-28 00:15 | 2014-02-25 | Miller Andrew | Officer - EVP, CFO | OPT+S | $54.75 | 3,750 | $205,313 | 4,584 | 0.0% |
| 2014-02-04 00:01 | 2014-01-31 | SMITH JOSEPH H | Officer - EVP, Bus Dev and GC | OPT+S | $51.15 | 50,000 | $2,557,500 | 11,181 | 0.0% |
| 2014-02-04 00:01 | 2014-01-31 | Miller Andrew | Officer - EVP, CFO | OPT+S | $53.10 | 63,375 | $3,365,453 | 4,584 | 0.0% |
| 2014-02-04 00:00 | 2014-01-31 | BISHOP JOHN L | Director, Officer - Chairman of the Board and CEO | OPT+S | $50.67 | 150,000 | $7,600,005 | 39,176 | 0.0% |
| 2014-01-29 00:07 | 2014-01-27 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $47.63 | 265 | $12,621 | 20,000 | 0.0% |
| 2014-01-22 00:12 | 2014-01-16 | SMITH JOSEPH H | Officer - EVP, Bus Dev and GC | OPT+S | $49.33 | 15,000 | $740,000 | 10,086 | 0.0% |
| 2014-01-22 00:07 | 2014-01-16 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $49.61 | 15,624 | $775,100 | 20,000 | 0.0% |
| 2014-01-22 00:06 | 2014-01-16 | BISHOP JOHN L | Director, Officer - Chairman of the Board and CEO | OPT+S | $49.38 | 100,000 | $4,937,500 | 37,220 | 0.0% |
| 2014-01-07 00:07 | 2014-01-03 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $45.66 | 6,357 | $290,244 | 20,000 | 0.0% |
| 2014-01-04 00:06 | 2014-01-02 | Miller Andrew | Officer - EVP, CFO | OPT+S | $45.92 | 2,437 | $111,900 | 2,683 | 0.0% |
| 2013-12-25 00:08 | 2013-12-23 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $46.51 | 10,000 | $465,072 | 20,000 | 0.0% |
| 2013-12-03 00:24 | 2013-11-27 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $45.49 | 21,328 | $970,211 | 20,000 | 0.0% |
| 2013-11-19 00:17 | 2013-11-15 | Miller Andrew | Officer - EVP, CFO | OPT+S | $42.70 | 13,813 | $589,815 | 2,683 | 0.0% |
| 2013-11-19 00:16 | 2013-11-14 | PERSING DAVID H | Director, Officer - Exec VP,Chief Med/Tech Officer | OPT+S | $42.18 | 5,000 | $210,900 | 645 | 0.0% |
| 2013-11-14 00:17 | 2013-11-08 | RENTON HOLLINGS | Director | OPT+S | $41.44 | 12,500 | $517,939 | 8,650 | 0.0% |
| 2013-11-14 00:16 | 2013-11-08 | PERSING DAVID H | Director, Officer - Exec VP,Chief Med/Tech Officer | OPT+S | $41.76 | 5,000 | $208,800 | 645 | 0.0% |
| 2013-11-07 00:09 | 2013-11-04 | Brown Thomas D | Director | OPT+S | $41.00 | 12,500 | $512,500 | 27,335 | 0.0% |
| 2013-10-31 00:38 | 2013-10-30 | PERSING DAVID H | Director, Officer - Exec VP,Chief Med/Tech Officer | OPT+S | $41.35 | 5,000 | $206,750 | 645 | 0.0% |
| 2013-10-31 00:36 | 2013-10-28 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $40.50 | 2,660 | $107,729 | 20,000 | 0.0% |
| 2013-10-28 23:12 | 2013-10-24 | MORTON DEAN O | Director | OPT+S | $40.26 | 12,500 | $503,231 | 15,650 | 0.0% |
| 2013-10-28 23:09 | 2013-10-24 | GUTSHALL THOMAS L | Director | SELL | $40.07 | 3,000 | $120,210 | 379,800 | -0.8% |
| 2013-10-28 23:09 | 2013-10-24 | FLOM KERRY | Officer - EVP, Regulatory Affairs | OPT+S | $39.79 | 101 | $4,019 | 19,899 | 0.0% |
| 2013-10-22 23:27 | 2013-10-18 | PERSING DAVID H | Director, Officer - Exec VP,Chief Med/Tech Officer | OPT+S | $40.59 | 20,000 | $811,850 | 177 | 0.0% |
| 2013-09-26 23:08 | 2013-09-24 | GUTSHALL THOMAS L | Director | SELL | $38.97 | 3,000 | $116,912 | 382,800 | -0.8% |
| 2013-09-19 23:41 | 2013-09-18 | PERSING DAVID H | Director, Officer - Exec VP,Chief Med/Tech Officer | OPT+S | $39.34 | 5,000 | $196,700 | 177 | 0.0% |
How to Interpret $CPHD Trades
Not every insider transaction in CPHD is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CPHD shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for CPHD
Insider activity data for CPHD is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CPHD, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.